[177Lu]Lu-NeoB is named as a drug or biological intervention in 4 clinical trials in our USA, China and UK trial registers, none of which are currently recruiting. The lead sponsor is Novartis Pharmaceuticals. Registered phases: Phase 1 and Phase 1/2. Conditions studied include Breast Cancer; Metastatic Neuroendocrine Prostate Cancer; Newly Diagnosed and Recurrent Glioblastoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (ClinicalTrials.gov ↗) Breast Cancer |
Phase 1/2 | Active, closed |
| NCT05739942 | Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (ClinicalTrials.gov ↗) Newly Diagnosed and Recurrent Glioblastoma |
Phase 1 | Active, closed |
| NCT05870579 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer |
Phase 1 | Active, closed |
| NCT06379217 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (ClinicalTrials.gov ↗) Metastatic Neuroendocrine Prostate Cancer |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 2 |
| Metastatic Neuroendocrine Prostate Cancer | 1 |
| Newly Diagnosed and Recurrent Glioblastoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Register | [177Lu]Lu-NeoB trials |
|---|---|
| Clinical trials in USA | 4 |
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how [177Lu]Lu-NeoB works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists [177Lu]Lu-NeoB (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.